Biotech · Private company
HiberCell, Inc.
Track this companyFree. Adds HiberCell, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials113 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- Imprime PGGPhase 2 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Imprime PGGPhase 2 · Pathologic Stage III Cutaneous Melanoma AJCC v8ClinicalTrials.gov · fetched Nov 12, 2026
- Imprime PGGPhase 2 · Malignant Neoplasm of BreastClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Pathologic Stage III Cutaneous Melanoma AJCC v8ClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Malignant Neoplasm of BreastClinicalTrials.gov · fetched Nov 12, 2026
- BelzutifanPhase 1 · Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- CDX-1140Phase 1 · Metastatic Pancreatic AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- HC-5404-FUPhase 1 · Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- HC-7366Phase 1 · Squamous Cell Carcinoma of Head and NeckClinicalTrials.gov · fetched Nov 12, 2026
- HC-7366Phase 1 · Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- odetiglucanPhase 1 · Metastatic Pancreatic AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)PHASE1 · RECRUITING · started Mar 24, 2026ClinicalTrials.gov NCT07401875 · fetched Nov 12, 2026
- Phase I Study of HC-7366 for Acute Myeloid LeukemiaPHASE1 · RECRUITING · started May 20, 2024ClinicalTrials.gov NCT06285890 · fetched Nov 12, 2026
- A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell CarcinomaPHASE1 · RECRUITING · started Apr 29, 2024ClinicalTrials.gov NCT06234605 · fetched Nov 12, 2026
- A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal AdenocarcinomaPHASE1 · TERMINATED · started Dec 15, 2022ClinicalTrials.gov NCT05484011 · fetched Nov 12, 2026
- A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)PHASE1 · TERMINATED · started Feb 23, 2022ClinicalTrials.gov NCT05121948 · fetched Nov 12, 2026
- Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)PHASE2 · COMPLETED · started Nov 9, 2021ClinicalTrials.gov NCT05159778 · fetched Nov 12, 2026
- Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable MelanomaPHASE2 · WITHDRAWN · started Aug 15, 2021ClinicalTrials.gov NCT04995094 · fetched Nov 12, 2026
- A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)PHASE1 · COMPLETED · started Jun 8, 2021ClinicalTrials.gov NCT04834778 · fetched Nov 12, 2026
- Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017PHASE1_PHASE2 · COMPLETED · started Jul 11, 2017ClinicalTrials.gov NCT03003468 · fetched Nov 12, 2026
- Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast CancerPHASE2 · COMPLETED · started Feb 22, 2017ClinicalTrials.gov NCT02981303 · fetched Nov 12, 2026
- A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin LymphomaPHASE2 · COMPLETED · started Dec 1, 2014ClinicalTrials.gov NCT02086175 · fetched Nov 12, 2026